(
358
Results
)
Filter
Only match titles
What are you looking for?
-
Category
-
Type
-
Year
-
Keywords
-
Author
Apply filters
Knowledge Hub
Collapse
-
Advances in allergen immunotherapy I
-
Allergen immunotherapy has a role in the era of biologics (Con&Pro Session: Con)
-
Basophil activation test results change in birch pollen sensitized patients during first season of immunotherapy
-
Basophil sensitivity during immunotherapy in grass pollen-allergic patients
-
Component Resolved Diagnosis and pollen Immunotherapy indication
-
Contraindications to venom immunotherapy and risk factors for adverse events: any left?
-
Cutting edge allergen immunotherapy
-
Exposome modulation and immunotherapy in infants at higher risk of respiratory allergies
-
Flash Talks on allergen immunotherapy
-
Flash talks on allergen Immunotherapy I
-
Flash talks on food allergy and immunotherapy
-
How to improve compliance of allergen immunotherapy in the clinic?
-
Immunotherapy in severe asthma (AIT)
-
Immunotherapy to food allergy
-
Improving patient care with allergen immunotherapy (AIT): Lessons learned from randomised control trials (RCT) and real world evidence (RWE) studies
-
Is specific immunotherapy useful in atopic dermatitis?
-
New Perspectives on Allergen Immunotherapy
-
New Perspectives on Allergen Immunotherapy
-
Oral food challenge versus biomarkers – are challenges still needed?
-
Oral food challenges thresholds for clinical reactions
-
Oral tolerance induced by ovalbumin modulates the cytokine profile and increases the frequency of CD4+FoxP3+Helios+ Treg expressing the GARP/LAP late-stage activation markers in antigen-stimulated cells of P.paulista wasp venom-sensitized mice
-
Prescribing immunotherapy to pollens in children: influence of geographical and sociological diversity
-
Safety and prediction of allergen immunotherapy
-
Standardisation of Allergen Immunotherapy products and Legal Considerations
-
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy
-
Oral immunotherapy in Food Allergy. What is the consensus?
-
Sustained unresponsiveness to tree nuts after low dose oral immunotherapy in children aged 9-24 months
Show more Event Resources (25)Show Less-
-
Allergen immunotherapy for respiratory allergy: quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool
-
Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs
-
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals – EAACI recommendations
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy
-
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
-
Placebo effects in allergen immunotherapy – An EAACI Task Force Position Paper
-
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
-
The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project
-
Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies – Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology task force
Show more Position Papers (8)Show Less-
-
“Allergen Harmony”: New data for a tailored and sustained food and respiratory immunotherapy effect
-
Allergen immunotherapy with allergoid-mannan conjugates: from basic science to clinical research
-
Best in both worlds – Demonstrating long-term effectiveness of allergy immunotherapy in the real world
-
Championing change: Is elimination of oral corticosteroid use in asthma achievable today?
-
Patients’ perspective : a must have for the future of Allergen Immunotherapy
-
Raising paediatric awareness through growing evidence for allergy immunotherapy – optimise the treatment of children suffering from respiratory allergy
-
Rethinking hereditary angioedema: What role can the first oral plasma kallikrein inhibitor play?
-
Setting a new standard for grass subcutaneous immunotherapy
-
Treating peanut allergy with oral immunotherapy: new data and practical experience
Show more Sponsored Symposia (7)Show Less-
-
Aeroallergen immunotherapy before five years of age and elderly
-
Allergen Immunotherapy and Biologicals
-
Allergen immunotherapy and co-evaluation of COVID-19 vaccines
-
Eosinophilic esophagitis and allergen immunotherapy
-
Health economics of allergen immunotherapy
-
Nocebo effect of allergen immunotherapy
Show more Task Forces (4)Show Less-
Website
Collapse
-
24/7/365 Telephone assistance in oral inmunotherapy with food
-
300 IR 5-grass pollen sublingual immunotherapy tablet for allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies
-
A comparison of conventional vs cluster updosing venom immunotherapy in children in a tertiary hospital
-
A dose ranging study of sting challenge and specific lgE, IgG4, venom skin test and basophil activation responses to ant venom immunotherapy with and without delta-inulin adjuvant
-
Absence of alpha-tryptase isoforms is associated with less severe adverse events during peanut-oral immunotherapy
-
Absence of early exposure to dietary antigens impairs the host capacity to establish oral tolerance to food proteins
-
Achieving Remission with Peanut Sublingual Immunotherapy
-
Active immunotherapy with recombinant Bet v 1
-
Adherence to venom immunotherapy : a french monocentric retrospective study
-
Adult-onset food protein-induced enterocolitis syndrome. Cytokine variations after positive oral food challenges
-
Advances in Allergen Immunotherapy
-
Advances in Allergen Immunotherapy (AIT)
-
Advances in Immunotherapy
-
Allergen Immunotherapy
-
Allergen Immunotherapy
-
Allergen Immunotherapy Improves Bronchial Epithelial Tolerance and Antiviral Responses in Patients with House Dust Mite Allergic Asthma
-
Allergen Immunotherapy Improves Bronchial Epithelial Tolerance and Antiviral Responses in Patients with House Dust Mite Allergic Asthma
-
Allergen Immunotherapy decreases biologicals use in allergic rhinitis with chronic rhinosinusitis with nasal polyps (CRSwNP)
-
Allergen Immunotherapy for the prevention of respiratory allergy
-
Allergen Immunotherapy in the Republic of Kazakhstan
-
Allergen immunotherapy
-
Allergen immunotherapy (AIT) in pregnancy, focus on the use of carbamylated monomeric allergoid
-
Allergen immunotherapy 1
-
Allergen immunotherapy 2
-
Allergen immunotherapy 3
-
Allergen immunotherapy 4
-
Allergen immunotherapy 5
-
Allergen immunotherapy 6
-
Allergen immunotherapy 7
-
Allergen immunotherapy in food allergy, what’s new?
-
Allergen immunotherapy in patients with allergic rhinitis and asthma associated with reduced risk of severe COVID-19
-
Allergen immunotherapy – Basic and clinical perspective
-
Allergen metabolism by human oral bacteria alters its allergenicity
-
Allergen-specific immunotherapy based on purified and modified Fel d 1 allergen from cat dander
-
Allergic, but still want them: A Mix Pet Dander Immunotherapy
-
AllergoOncology: Application of the basophil activation test (BAT) in pre-clinical testing and the first-in-class clinical trial of anti-cancer IgE immunotherapy
-
Allergy Therapeutics – Setting a new standard for grass subcutaneous immunotherapy
-
An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)
-
Analysis of immunological and cellular tolerance biomarkers during bee venom immunotherapy
-
Analyzing Factors Influencing Adherence to Classify Adherence Levels in Patients Treated with Allergen Immunotherapy
-
Anaphylaxis with omeprazole presenting positive oral challenge to esomeprazole
-
Application of allergen standardization in allergen-specific immunotherapy (AIT)
-
Are LADDERS the new Oral Food Challenge?
-
Are oral food challenges still necessary for diagnosing food allergy
-
Artificial intelligence and precision immunology: pioneering biomarker discovery in allergen immunotherapy
-
Assessing protocol variability for FPIES oral food challenges
-
Asthma phenotype markers did not affect allergen immunotherapy effectiveness
-
Basophil activation test as a predicting tool for effective Pru p 3 sublingual immunotherapy response in lipid transfer protein allergy
-
Best candidate for allergen-specific immunotherapy
-
Blocking antibodies from food immunotherapy unravelled at the molecular level
-
Build-Up of Wasp Venom Immunotherapy with Alutard-Depot SQ during Supply Shortage: A Retrospective Case Series
-
Bumblebee venom allergy as an emerging occupational allergy: safety and efficacy of bumblebee venom immunotherapy in a large single-center cohort
-
Carry-over effect of 300 IR house dust mite sublingual immunotherapy tablet and relationship with disease activity: a post hoc analysis
-
Characterization of adaptative immune cells after double-blind placebo-controlled oral food challenges
-
Clinical Assessment of Specific Immunotherapy Efficacy in Individuals with House Dust Mite-Induced Allergic Rhinoconjunctivitis
-
Clinical Characteristics of Anaphylaxis Secondary to Subcutaneous Allergen-Specific Immunotherapy in a Pediatric Hospital in Mexico
-
Clinical Evaluation of subcutaneous immunotherapy (SCIT) containing a mixture of mites, in depot polymerized formulation without dilutional effect. Results from a prospective multicenter study
-
Clinical and immunological comparison between two subcutaneous immunotherapy products in children with allergic rhinitis
-
Clinical evaluation of an immunotherapy treatment with Vespa velutina venom in allergic patients. Results from a prospective multicenter Study: W-STING Study
-
Clinical outcomes used in allergen immunotherapy in allergic asthma in the era of Data Science
-
Commercial product for oral food challenges: CON
-
Commercial product for oral food challenges: PRO
-
Comparison of the efficacy of subcutaneous and sublingual immunotherapy for the treatment of allergic asthma in children
-
Coordinated specific IgG2 and IgE responses are associated with high clinical benefit of allergen immunotherapy with 300 IR house dust mite sublingual tablets in a large European cohort
-
Criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice. CHOICE project results from Interim analysis 2023: PATIENT’S RESULTS
-
Criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice. CHOICE project results from Interim analysis 2023: DOCTOR’S RESULTS
-
DBV Technologies – Epicutaneous route: an innovative potential approach to food immunotherapy
-
DRAGO Application: Implementing Adherence and to House Dust Mite Allergen Immunotherapy
-
Delving deeper in allergen immunotherapy
-
Demystifying the fear of lack of adherence to sublingual immunotherapy (SLIT)
-
Designing Modified Variants of Ara h 1 and Ara h 2 for Safe and Effective Immunotherapy
-
Development and implementation of an intelligence platform for management of allergen immunotherapy in China
-
Development of a thermosensitive poloxamer formulation designed to provide a controlled release of the active pharmaceutical ingredient in birch pollen allergen immunotherapy
-
Development of standardised challenge meals to meet regulators demands for Oral Food Challenges
-
Differential study of whole genome expression profiles of peripheral blood mononuclear cells in children with dust mite specific immunotherapy for asthma
-
Direct oral provocation in adults (without skin testing first)
-
Discovering new horizons in allergen immunotherapy
-
Do sIgE predict the oral food challenge outcomes in children with fish allergy?
-
Do sIgE predict the oral food challenge outcomes in children with fish allergy?
-
Do we need commercial products for oral food challenges?
-
EUROBAT ORAL ABSTRACT SESSION 1
-
EUROBAT ORAL Abstract Session 2
-
Early immunotherapy with aeroallergens and impact on future allergy
-
Early inflammatory reactions in mice after immunotherapy with an allergen microcrystalline tyrosine adsorbate
-
Effect of 300 IR house dust mite sublingual immunotherapy tablet in paediatric patients and relationship with disease activity
-
Effect of allergen – specific immunotherapy on PFS symptoms
-
Effect of allergen specific immunotherapy on PFS symptoms
-
Effect of allergen specific immunotherapy on PFS symptoms
-
Effect of non-specific Lipid Transfer Protein (nsLTP) allergies in oral and gut epithelial barrier integrity
-
Effect of sublingual immunotherapy on allergic rhinitis: Real-life data analysis
-
Effectiveness of sublingual immunotherapy in patients with atopic dermatitis allergic to house dust mite: an open label extension study
-
Effectiveness of sublingual immunotherapy in patients with atopic dermatitis allergic to house dust mite: an open label extension study
-
Efficacy and Safety of Hymenoptera Venom Immunotherapy
-
Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
-
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
-
Efficacy and safety of HDM-specific subcutaneous immunotherapy on atopic dermatitis
-
Efficacy and safety of sublingual immunotherapy for mite in children and adolescents with AR
-
Efficacy of virus-like particle (VLP)-based immunotherapy in a mouse model of HDM allergy
-
Epicutaneous Immunotherapy with Peanut Allergy
-
Evaluation of auditory function in children with allergic rhinitis treated with specific immunotherapy
-
Evaluation of the Oral Food Challenge Test Using Baked Milk and Baked Egg in Children with Allergies to Small Amounts of Cow’s Milk or Cooked Hen’s Egg
-
Evaluation of the efficacy, adverse effects, and cost-effectiveness of sublingual immunotherapy with dominant allergens for allergic rhinitis due to respiratory allergens in adults and children
-
Evaluation of total Immunoglobulin D in sublingual immunotherapy for allergic rhinitis
-
Exacerbation of eosinophilic esophagitis in a child with seasonal allergic rhinitis during sublingual immunotherapy
-
Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy
-
Exploring the Protective Potential: Subcutaneous Immunotherapy associated with C. acnes as a reductor of COVID-19 Severity in Older Patients – A Single-Center Observational Study
-
Factors associated with severity of reactions during oral food challenge test
-
Field Stings in Patients Undergoing Hymenoptera Venom Immunotherapy in a Healthcare Area of Central Spain
-
First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma
-
Flash talks on Allergen Immunotherapy 1
-
Flash talks on Allergen Immunotherapy 2
-
Flash talks on Allergen Immunotherapy 3
-
Flash talks on Allergen Immunotherapy 4
-
Food-allergen immunotherapy : how do I get started?
-
From allergen molecules to allergy management: can molecular diagnosis improve allergen immunotherapy efficacy?
-
Giving birth to a food allergen: from oral tolerance to the epithelial barrier dysfunction
-
Global Stage Session 3 – Successes and challenges of Immunotherapy
-
Graded oral challenge to delabel suspected non-steroidal anti-inflammatory drugs (NSAIDs) hypersensitivity in children
-
Graded oral challenge to delabel suspected non-steroidal anti-inflammatory drugs (NSAIDs) hypersensitivity in children
-
House dust mite sublingual immunotherapy comprehensively improves asthma and allergic rhinitis in children and adolescents
-
How allergists around the world perceive innovation in the context of allergen Immunotherapy AIT: an international survey
-
Hymenoptera venom immunotherapy with 210 minutes Ultra-Rush protocol: patient profile and potential risk factors for systemic reactions
-
ILIT.NU: Intralymphatic immunotherapy and placebo affected cSMS similarly in grass pollen allergic individuals in a large clinical trial
-
ILIT.NU: Titration of Allergen for Treatment of Grass Pollen Induced Rhinoconjunctivitis with Intralymphatic Immunotherapy
-
IgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens
-
IgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens
-
Immune mechanisms of food immunotherapy
-
Immunotherapy for LTP allergy
-
Immunotherapy for food allergy. What’s new?
-
Immunotherapy in food allergy
-
Immunotherapy in the clinic
-
Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results
-
Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results
-
Impact of Security Measures Implementation in Subcutaneous Allergen Immunotherapy Administration at a Pediatric Hospital in Mexico
-
Impact of a 3-tree sublingual immunotherapy liquid formulation in birch family pollen-allergic patients on prevention of disease progression and/or asthma onset
-
Impact of different prophylactic sublingual immunotherapy regimes on peanut allergy prevention in Brown Norway rats
-
Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study
-
Impact of liquid sublingual immunotherapy with mixed pollen allergens on asthma prevention in polyallergic patients: results from the real-world EfficAPSI study
-
Indefinite immunotherapy with different extracts in systemic mastocytosis
-
Innovations in Food Allergy Immunotherapy
-
Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children
-
Intestinal-restricted location of allergen-specific regulatory T cells is driven by oral consumption of the allergen in murine models
-
Intestinal-restricted location of allergen-specific regulatory T cells is driven by oral consumption of the allergen in murine models
-
Intralymphatic immunotherapy of allergic rhinoconjunctivitis with grass allergoid microcrystalline tyrosine adsorbate produced reduced medication use and symptoms: a double-blind placebo-controlled trial
-
Intralymphatic immunotherapy with aluminium hydroxide based grass allergen reduced medication use in patients with allergic rhinoconjunctivitis: a double-blind randomized placebo-controlled trial
-
Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates allergic response in a murine model of allergic rhinitis
-
Is there still a role for oral corticosteroids in the management of CRS
-
Isolated Codeine Allergy with Evidence of Tolerance to Oral Morphine: A Case Report
-
Kinetics of IgG4 after Vespula venom immunotherapy administered with an ultra-rush protocol
-
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Reducing Infectious Events in Allergic Rhinitis Patients with and without Asthma
-
Management of fish allergy based on Oral Food Challenge
-
Microneedles-based transdermal allergen specific immunotherapy protects against gliadin induced anaphylaxis in a mouse model
-
Minimum resources to run an immunotherapy clinic safely
-
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
-
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
-
Modulation of B cell memory responses by house dust mite allergen immunotherapy
-
Monitoring for early warning signs of asthma attacks and response to treatment with oral corticosteroids using the Albus Home contactless monitoring system
-
Monitoring response to immunotherapy
-
Mucosal delivery of allergen-specific immunotherapy with vaccine adjuvants suppresses allergic disease through both humoral and cellular immune mechanisms
-
Multiple food protein-induced enterocolitis syndrome in a child with 8 positives oral food challenges
-
Murine IgG1 corresponding to human IgG4 increased by subcutaneous immunotherapy suppressed activation of group 2 innate lymphoid cells
-
Navigating Oral Food and Drug Provocation Tests: Assessing Tolerance and Safety in Clinical Settings
-
New directions in immunotherapy and vaccinology
-
Nut allergy: the importance of molecular diagnosis and oral food challenge testing
-
Nut immunotherapy – Is it ready for prime time?
-
One-strength dose escalation using a birch pollen allergoid for subcutaneous immunotherapy is safe and well-tolerated in children, adolescents and adults
-
Oral Abstract Session 1
-
Oral Abstract Session 2
-
Oral Abstract Session 3
-
Oral Abstract Session 4
-
Oral Abstract Session 5
-
Oral Abstract Session 6
-
Oral Administration of Ginsenoside F1 Attenuates Allergic Atopic Dermatitis by Modulating T cell Activation
-
Oral Challenge Tests in an Outpatient Clinic: Is It Safe?
-
Oral Food Challenge Approaches in Food Protein-Induced Enterocolitis Syndrome: A Systematic Review
-
Oral Food Challenges in Children’s Health Ireland
-
Oral Mite Anaphylaxis after eating homemade Pizza with contaminated wheat flour
-
Oral Sebetralstat for On-demand Treatment of Hereditary Angioedema: Phase 3 KONFIDENT Trial Results
-
Oral food Challenge in Adults
-
Oral food challenge materials and protocols
-
Oral food challenge outcomes in a pediatric allergy outpatient office of a tertiary hospital
-
Outcomes of Bee Re-sting After Cessation of Venom Immunotherapy
-
Passive immunotherapy with anti-Bet v 1 mAb
-
Patient preference: A multinational discrete-choice-experiment (DCE) in pollen allergen immunotherapy (AIT)
-
Patients undergoing immunotherapy with Alternaria alternata: prevalence of asthma and co-sensitization to other allergens
-
Peanut allergens differently adhere to oral epithelia
-
Pediatric patients undergoing immunotherapy with alternaria alternata: demographic and clinical characterization
-
Poloxamer formulation for allergen immunotherapy reduces systemic allergic reactions in a mouse model
-
Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system
-
Predicting clinical response to allergen-specific immunotherapy to D. pteronyssinus using serological pre-treatment parameters
-
Predicting the Efficacy of Allergen Immunotherapy in Asthma Based on Initial-Year Outcome: Insights from the Estimated Daily Symptom and Medication Score
-
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
-
Prospective, pilot, phase 1 study of iPUMP© in patients starting sublingual allergen immunotherapy (Staloral©)
-
Reactions Due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers
-
Real-life Non-interventional Post authorization Safety Study with the SQ tree sublingual immunotherapy tablet
-
Real-life experience of allergen-specific immunotherapy
-
Real-world change in asthma symptom control and oral corticosteroid use in patients with severe asthma treated with mepolizumab stratified by atopic status: Post hoc analysis of REALITI-A at 2 years
-
Risk Factors for Early Adverse Events of Sublingual Immunotherapy for Allergic Rhinitis and their Impact on Short-term Treatment Outcomes
-
Role of sublingual immunotherapy in management of patients with moderate to severe allergic rhinitis; one year study
-
SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet is well-tolerated in children with inadequately controlled HDM allergic asthma
-
Safety and Tolerability of Rush Updosing Using a Mugwort Allergoid Extract for Subcutaneous Allergen Immunotherapy
-
Safety and tolerability of in-season initiation of subcutaneous and sublingual allergen immunotherapy with SQ grass pollen products: a comprehensive review
-
Safety and tolerance response of a two day rush protocol treatment in immunotherapy using purified Apis mellifera dry Honeybee venom extract
-
Safety of a cluster strategy, effectiveness and immunological changes in allergic children sensitized to house dust mites with native and modified subcutaneous immunotherapy treatment
-
Safety of subcutaneous immunotherapy with mixtures of two allergens at maximum concentration: 10 year real-world data
-
Safety profile in clinical trials of sublingual immunotherapy with carbamylated monomeric allergoid
-
Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of Demographics and Attack Characteristics from the Open-label KONFIDENT-S Trial
-
Short-term benefits of sublingual immunotherapy in routine clinical practice: Patient Benefit Index by class in the observational, prospective, longitudinal study PRACTIS
-
Short-term benefits of sublingual immunotherapy in routine clinical practice: deciphering factors influencing the patient satisfaction in the observational, prospective, longitudinal study PRACTIS
-
Specific IgE and IgG4 changes in adults undergoing peanut immunotherapy combined with omalizumab
-
Stallergenes Greer – “Allergen Harmony”: New data for a tailored and sustained food and respiratory immunotherapy effect
-
Subcutaneous Allergen-specific Immunotherapy in Pediatric Age – a level II hospital experience
-
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
-
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe in a pre/co-seasonal treatment regimen – a subgroup comparison
-
Sublingual dust mite allergen immunotherapy reduces respiratory infections in children with allergic rhinitis
-
Sublingual immunotherapy for house dust mite allergy induces expansions of allergen-specific memory B cells expressing CD29 and downregulating IL4Rα
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy in Poland and EU
-
Successful immunotherapy with cow’s milk and omalizumab in a 24-year-old patient with extreme cow’s milk allergy
-
Sympout study: Evolution of clinical parameters in a pediatric population allergic to pollens or house dust mites treated with sublingual immunotherapy in liquid formulation standardized in TBU/ml
-
Sympout study: Need of medication for symptom control in patients with rhinitis and/or bronchial asthma due to house dust mites or pollens in treatment with sublingual immunotherapy in a standardized liquid formulation in TBU/ml
-
Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen–induced allergic rhinitis
-
Systemic allergic reactions to subcutaneous allergen immunotherapy – A single center experience
-
TAPAS – a long-term non-interventional study evaluating MCT (MicroCrystalline Tyrosine)-associated allergoids shows non-inferiority of clinical effectiveness in children compared to adults during a 3-year course of allergen immunotherapy
-
The Bacterial Lysate 0M-85BV reduces risk for exacerbations and oral corticosteroids in allergic asthma: A retrospective parallel group-controlled study
-
The Efficacy and Safety of Stepwise Oral Food Challenge in Children with Hen’s Egg Allergy
-
The Quest for Tolerance in Allergen Immunotherapy
-
The Role of Oral Food Challenges in Clinical Trials: Necessity or Redundancy?
-
The effect of the sphenopalatine ganglion acupuncture on the clinical efficacy of cluster immunotherapy in patients with allergic rhinitis
-
The epicutaneous immunotherapy for peanut allergy: most recent results and perspectives
-
The journey to registration: challenges for allergen immunotherapy trials
-
The role of Innate Lymphoid Cells in food allergy and oral tolerance
-
The role of skin testing, serum IgE, and extended oral challenges in diagnosing childhood beta-lactam allergy: The CHildren Antibiotic Delabeling (CHAD) study
-
The successful switch of Hymenoptera venom immunotherapy (VIT) to a different manufacturer
-
The utility of basophil activation testing in honey bee venom allergy diagnosis and venom immunotherapy
-
Trained innate immunity and immunotherapy
-
Treatment of HAE Attacks with Anticipated Future Oral On-demand Therapies as Reported by Patients
-
Treatment satisfaction and health literacy among patients undergoing allergen-specific immunotherapy -Data from a tertiary allergy centre
-
Understanding the Patient: Their Preferences for Venom Immunotherapy
-
Unmasking Mite Anaphylaxis – a Hidden Oral Allergen
-
Urinary PGDM is not elevated during oral food challenges for food protein-induced enterocolitis syndrome
-
Using the AllergyVax app to increase adherence to allergen subcutaneous immunotherapy
-
Venom Allergen Immunotherapy in Children: Efficacy, Persistence of Efficacy and Impact on Quality of Life
-
Venom Allergen Immunotherapy in Children: Efficacy, Persistence of Efficacy and Impact on Quality of Life
-
Venom Immunotherapy in children and adolescents: safety and outcome in a study group from a third level Italian center
-
Venom immunotherapy in children – do we have an age limit ? (case report)
-
Venom immunotherapy in mastocytosis
-
Why So Sensitive? Identifying New Allergic Sensitization in Patients On Subcutaneous Immunotherapy (SCIT)
-
Сytokine profile in patients with allergic rhinitis during allergen-specific immunotherapy with added vitamin D
-
Сytokine profiles in patients with allergic rhinitis during allergen-specific immunotherapy with and without added vitamin D
-
“Picking the Harmony”: The Science Behind Immunotherapy Treatments
-
“Rhythm of Success”: Sustaining Benefits in Allergen Immunotherapy
-
“Tuning In”: Patient Profiles Orchestrating Optimized Response to Immunotherapy
-
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI trial): baseline peanut-specific T cell responses of participants
-
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI trial): baseline peanut-specific T cell responses of participants
-
Advances in Oral Immunotherapy
-
Allergen specific IgE is a stronger predictor of remission following Peanut Oral Immunotherapy in children aged 1-10 years
-
Analysis of epinephrine use during peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1 to 3 years
-
Antioxidant pine nut protein hydrolysate as a therapeutic oral immunotherapy agent in a murine model of pine nut allergy
-
B Cell Repertoires and Phenotypes in Food Allergy and Oral Immunotherapy
-
Biologicals as adds on in oral immunotherapy for IgE mediated food allergy
-
Descriptive study of the evolution of patients after oral immunotherapy with milk at the Hospital Universitario Fundación Alcorcón
-
Evaluation of Patients with Venom Immunotherapy Indication When Immunotherapy Preparation Could Not Be Obtained
-
Exposure-adjusted safety of peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1-3 years (POSEIDON trial)
-
FERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without OmalizumabFERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without Omalizumab
-
Food oral immunotherapy monitoring with OITcontrol® is related to reduced number of home adverse reactions and better treatment compliance compared with paper-based monitoring
-
Food oral immunotherapy monitoring with OITcontrol® is related to reduced number of home adverse reactions and better treatment compliance compared with paper-based monitoring
-
High degree of desensitization after one year of early-life peanut oral immunotherapy – SmaChO Randomized Controlled Trial
-
Immunologic profile and safety of milk oral immunotherapy in children with severe cow’s milk allergy – a series of cases
-
Impact of participant baseline factors on exposure-adjusted incidence of treatment-related adverse events during peanut oral immunotherapy
-
Increase in maximum tolerated dose and decrease in symptom severity during food challenge in a clinical trial of oral immunotherapy for peanut allergy in children aged 1 to 3 years
-
Long-term Follow-up After Peanut Oral Immunotherapy During Preschool Years: Lessons from the IMPACT Trial
-
Molecular tools in support to walnut oral immunotherapy
-
NOVEL MULTI-NUTS ORAL IMMUNOTHERAPY PROTOCOLS (ALPEDIA-NOITs)
-
One-year follow-up of children who achieved sustained unresponsiveness following early oral immunotherapy for various allergens
-
Oral Immunotherapy for Adults with Food Allergies
-
Oral Immunotherapy with omalizumab in an adult patient with severe milk and egg allergy
-
Oral immunotherapy (OIT) in walnut and hazelnut co-allergic patients: ELISA inhibition studies to direct treatment approach
-
Oral immunotherapy decreases expression of pro-inflammatory genes upon re-exposure to allergen in egg allergic children
-
Oral immunotherapy in cow’s milk allergic patients
-
Oral immunotherapy protocols for milk / egg
-
Oral immunotherapy protocols for milk / egg
-
Oral immunotherapy protocols for milk / egg
-
Outcomes of low-dose peanut food challenges in preschoolers when initiating peanut oral immunotherapy
-
Prognostic value of specific IgE ratios in the tolerance of oral immunotherapy with egg allergy
-
Real-life experience with long-term oral immunotherapy for nut allergic children: A single center study from Luxembourg
-
Real-life experience with long-term oral immunotherapy for nut allergic children: A single center study from Luxembourg
-
Safety of oral immunotherapy in preschool aged children with single and multiple food allergy (the ORKA trial): a prospective intervention study
-
The change in quality of life of adults with food allergy treated with oral immunotherapy
-
5-year patient-reported outcomes after oral immunotherapy using heat-modified peanuts: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
-
5-year patient-reported outcomes after oral immunotherapy using heat-modified peanuts: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
Show more Sessions (291)Show Less-